Received Dec 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | HD249 | LA |
only the diluent of Shingrix was administered to the patient.; only the diluent of Shingrix was administered to the patient.; This non-serious case was reported by a nurse via sales rep and described the occurrence of inappropriate preparation of medication in a 70-year-old female patient who received Herpes zoster (Shingrix) (batch number HD249, expiry date 28-APR-2027) for prophylaxis. Concomitant products included pravastatin. On 03-OCT-2025, the patient received Shingrix (left deltoid). On 03-OCT-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: only the diluent of Shingrix was administered to the patient.) and inappropriate dose of vaccine administered (Verbatim: only the diluent of Shingrix was administered to the patient.). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date 5-DEC-2025 It was reported that only received the diluent of Shingrix was administered to the patient. No adverse events were observed following the administration.
PRAVASTATIN